Clinical trials: Primary Insomnia
Sleep Initiation and Maintenance Disorders
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
This study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia
- Trial name
- NCT00426816
- Testing
- SB-649868
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Primary Insomnia
Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia
A six-month study to determine the safety and efficacy with an additional open-label extension to determine the long-term safety of eszopiclone in the treatment of adult subjects with primary insomnia.
- Trial name
- NCT01710631
- Testing
- eszopiclone 3 mg
- Volunteers
- 791 people
- Sponsor
- Sumitomo Pharma America, Inc.
Insomnia, Migraine
Treatment of Insomnia in Migraineurs
It is hypothesized that treating insomnia in migraineurs, many of whom also have tension headaches, prolongs total sleep time to the extent that it decreases overall headache frequency.
- Trial name
- NCT00812214
- Testing
- eszopiclone
- Volunteers
- 113 people
- Sponsor
- MedVadis Research Corporation
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)
The primary objective of the study is to evaluate the hypnotic efficacy of zolpidem-MR 12.5 mg in comparison with placebo, when administered over a long-term period, on an "as needed" basis, in patients with chronic primary…
- Trial name
- NCT00425243
- Testing
- zolpidem-MR (SL800750)
- Where
- United States
- Volunteers
- 1,025 people
- Sponsor
- Sanofi
Primary Insomnia
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects with primary insomnia on subjective sleep measures, compared to placebo.
- Trial name
- NCT00352144
- Testing
- Eszopiclone
- Where
- 58 sites in United States
- Volunteers
- 830 people
- Sponsor
- Sumitomo Pharma America, Inc.
Primary Insomnia
VEC-162 Study in Adult Patients With Primary Insomnia
The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.
- Trial name
- NCT00548340
- Testing
- VEC-162 20 mg, VEC-162 50 mg
- Where
- 35 sites in United States
- Volunteers
- 322 people
- Sponsor
- Vanda Pharmaceuticals
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
The aim of the study is to investigate the effects of oral melatonin and zinc supplementation on core features in individuals with ME/CFS
- Trial name
- MelatoZincME (NCT05454683)
- Testing
- melatonin plus zinc, isomaltose and magnesium stearate
- Where
- Spain
- Volunteers
- 106 people
- Sponsor
- Laboratorios Viñas, S.A.
Sleep Initiation and Maintenance Disorders, Insomnia
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year
The purpose of the study is to assess efficacy and safety of eplivanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- EPLILONG (NCT00253903)
- Testing
- eplivanserin (SR46349)
- Where
- 14 sites in United States, Argentina and 12 more
- Volunteers
- 1,155 people
- Sponsor
- Sanofi
Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder
A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and…
- Conditions
- Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias, Sleep Disorders
- Trial name
- Jade (NCT00561574)
- Testing
- Esmirtazapine
- Volunteers
- 259 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Initiation and Maintenance Disorders, Mental Disorders
A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
To investigate the long-term efficacy and safety of treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo, in participants with chronic primary insomnia.
- Conditions
- Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders
- Trial name
- NCT00631657
- Testing
- Esmirtazapine
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Primary Insomnia
Almorexant in Primary Insomnia
The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters.
- Trial name
- Insomnia (NCT00640848)
- Testing
- almorexant
- Where
- 27 sites in Austria, Denmark and 8 more
- Volunteers
- 161 people
- Sponsor
- Midnight Pharma, LLC
Insomnia
A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia
This is a randomized, double-blind, placebo-controlled, multicenter trial with a 4-way crossover design. Elderly subjects with primary insomnia who meet screening requirements will initially be randomized into the study and…
- Trial name
- NCT00748592
- Testing
- PD 0200390
- Sponsor
- Pfizer
Insomnia
A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
To evaluate the long-term safety and efficacy of eszopiclone administered for 12 weeks in elderly subjects with primary chronic insomnia.Administration of eszopiclone 2 mg daily at bedtime for 12 weeks in elderly subjects with a…
- Trial name
- NCT00386334
- Testing
- Eszopiclone
- Where
- 82 sites in United States
- Volunteers
- 388 people
- Sponsor
- Sumitomo Pharma America, Inc.
Insomnia
Investigation of the Efficacy and Safety of CHI-921 in Insomnia.
Insomnia is a disorder where people are having trouble sleeping and can include difficulty falling asleep, staying asleep and waking up too early, as well as having unrefreshing sleep.
- Trial name
- NCT03984604
- Testing
- CHI-921
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Canopy Growth Corporation
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients
KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients.
- Trial name
- NCT02087722
- Testing
- KI1001
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia
The aim of this trial was to assess the efficacy and safety of Eschscholtzia Californica (EC) in treating patients having psycho-physiologic insomnia in a double-blind randomised placebo controlled trial during a 28-day treatment…
- Trial name
- NCT02183233
- Testing
- Eschscholtzia Californica
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Sleep Initiation and Maintenance Disorders, Insomnia
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects…
- Trial name
- NCT00280423
- Testing
- GW679769
- Where
- 71 sites in United States, Canada
- Volunteers
- 342 people
- Sponsor
- GlaxoSmithKline
Primary Insomnia
30 Days in Home Use and Home Use Patterns Over 6 Months
This study will build upon a previously approved protocol entitled "A multi-center prospective, blinded, randomized crossover study to compare the Cerêve Sleep System at two different temperatures in primary insomnia patients"…
- Trial name
- NCT01882699
- Testing
- Cereve Sleep System
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cereve, Inc.
Primary Insomnia
Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs
This will be a multi-center, randomized, blinded, comparative, placebo-controlled, 4 arm crossover study in patients with primary insomnia.
- Trial name
- NCT00683436
- Testing
- Adipiplon, Ambien CR
- Where
- 9 sites in United States
- Volunteers
- 84 people
- Sponsor
- Neurogen Corporation
Insomnia, Insomnia (Moderate)
ASV Therapy for Insomnia
This will be a single center, prospective study designed to evaluate the effect of adaptive servo ventilation therapy on insomnia severity among patients with moderate to severe chronic insomnia.
- Trial name
- NCT07011966
- Testing
- ASV therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ResMed